Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
The British Journal of Radiology|March 27, 2020
A comparison of arterial spin labelling with catheter angiography in evaluating arteriovenous malformations: a systematic reviewSanjeev Ramachandran, Deyashini Mukherjee, Jonathan Delf, et al.Frontiers in Oncology|February 20, 2014
Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinationsAlexey Goltsov, Simon P Langdon, Gregory Goltsov, et al.Cellular Signalling|October 15, 2011
Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibitionAlexey Goltsov, Dana Faratian, Simon P Langdon, et al.Cellular Signalling|October 19, 2010
Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibitionAlexey Goltsov, Dana Faratian, Simon P Langdon, et al.Oxidative Medicine and Cellular Longevity|January 16, 2016
NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted ImmunotherapiesHilal S Khalil, Simon P Langdon, Ibrahim H Kankia, et al.Journal of Biotechnology|December 3, 2014
Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cellsHilal S Khalil, Alexey Goltsov, Simon P Langdon, et al.Disease Models & Mechanisms|August 14, 2012
Characterising the tumour morphological response to therapeutic intervention: an ex vivo modelAnne Savage, Elad Katz, Alistair Eberst, et al.Oncotarget|October 8, 2016
A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cellsHilal S Khalil, Simon P Langdon, Alexey Goltsov, et al.Cells|June 12, 2014
Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapyAlexey Goltsov, Yusuf Deeni, Hilal S Khalil, et al.Current Drug Targets|September 15, 2012
Engineering simulations for cancer systems biologyJames Bown, Paul S Andrews, Yusuf Deeni, et al.Pageof 2